Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
Status:
Not yet recruiting
Trial end date:
2024-11-21
Target enrollment:
Participant gender:
Summary
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled,
parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the
combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in
participants with cirrhosis with features of portal hypertension.